Developing and filing for both small-molecule and biological cancer therapies forms a key part of Aurobindo’s strategy to target higher-value products. Aidan Fry examines the company’s plan in this Generic’s bulletin Dec 2017 article.
Aurobindo aims at cancer as it climbs the value chain Read More »
East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Quetiapine Fumarate Extended-Release Tablets, 50 mg, 150 mg, 200 mg, 300mg and 400mg. The Division of Bioequivalence has determined Aurobindo Pharma Limited’s Quetiapine Fumarate Extended-Release Tablets 50 mg, 150 mg, 200 mg, 300 mg, and 400
Aurobindo Receives FDA Approval for Quetiapine Fumarate Extended Release Tablets. Read More »